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ListeriaCasein kinase 2 (CK2) is a pleiotropic serine/threonine kinase that regulates numerous cellular processes and
is essential to the infectious cycle of several viruses. Here we investigated the potential role of CK2 in vaccinia
virus (VACV) infection. We used the CK2 inhibitor TBB and found that CK2 inactivation impaired VACV dis-
semination and actin tail formation. We used RNAi and conﬁrmed that CK2 depletion impaired VACV actin
tail formation. Furthermore, we designed a recombinant virus that allowed us to speciﬁcally detect cell-
associated enveloped viruses (CEVs) at the plasma membrane and demonstrated that CK2 inactivation
does not affect CEV formation. Finally, we showed that CK2 depletion impaired the recruitment of Src to
CEVs. We discuss the possibility that CK2 may stimulate the A36-dependent recruitment of Src through
A36 phosphorylation.
© 2011 Elsevier Inc. All rights reserved.Introduction
Orthopoxvirus are large, enveloped, double-stranded DNA viruses
including vaccinia virus (VACV), variola virus (VARV), and monkey-
poxvirus (MPXV). VARV was the causative agent of human smallpox,
and was declared eradicated in 1980 following a global immunization
campaign that used live VACV as a vaccine. MPXV can cause a zoonot-
ic infection that results in a serious smallpox-like illness in humans
with low rate of secondary human-to-human transmission (Damon,
2007; Moss, 2007). Occurrence of human monkeypox was discovered
in the rain forest of Central and West Africa in 1970, and outbreaks
were recently reported in the Democratic Republic of Congo
(Rimoin et al., 2007, 2010).
VACV exploits host cell biology to replicate and spread from the
primary infected cell to the neighboring cells. After entry into the
host cell, VACV replicates in viral factories in the cytoplasm where in-
fectious intracellular mature viruses (IMVs) are produced. A subset of
IMVs is subsequently transported to the trans-Golgi network and
early endosome to acquire a two membrane wrapping leading to for-
mation of intracellular enveloped viruses (IEVs) (Hiller and Weber,f Medicine, 295 Congress Ave,
737 2630.
.
rights reserved.1985; Schmelz et al., 1994). IEVs are transported on microtubules to
the cell periphery where fusion with the plasma membrane exposes
cell-associated enveloped viruses (CEVs) on the cell surface, or re-
leases extracellular enveloped viruses (EEVs) (Hollinshead et al.,
2001; Rietdorf et al., 2001; van Eijl et al., 2002; Ward and Moss,
2001a). CEVs are capable of initiating an outside-in signaling cascade
that promotes actin polymerization beneath the plasma membrane
enabling efﬁcient cell-to-cell spread of the virus (Smith and Law,
2004; Smith et al., 2002).
The process of actin tail formation is initiatedwith the phosphoryla-
tion of tyrosine residues 112 and 132 of the viral protein A36 by kinases
of the Src and Abl family (Frischknecht et al., 1999; Katz et al., 2003;
Newsome et al., 2004, 2006; Reeves et al., 2005, 2011). Phosphorylation
of A36 leads to the recruitment of Nck, Grb2, WASP interacting protein
(WIP), and neural Wiskott–Aldrich syndrome protein (N-WASP)
(Frischknecht et al., 1999; Moreau et al., 2000; Newsome et al., 2004;
Scaplehorn et al., 2002). Ultimately, the ability to form actin tails relies
on the interaction of N-WASP with the Arp2/3 complex, a nucleator of
actin polymerization (Moreau et al., 2000; Weisswange et al., 2009).
Similar to VACV, intracellular bacterial pathogens such as Listeria
monocytogenes, Shigella ﬂexneri, and Rickettsia conorii exploit the host
actin polymerization machinery to acquire actin based motility. Recent
studies have established the requirement of casein kinase 2 (CK2) for L.
monocytogenes actin-dependent spreading (Chong et al., 2009). Here,
we explored the potential role of the pleiotropic serine/threonine
144 D.E. Alvarez, H. Agaisse / Virology 423 (2012) 143–151kinase CK2 in VACV infection. To date, more than 300 cellular sub-
strates were described for CK2 including signaling proteins, transcrip-
tion factors, and cytoskeleton structural proteins. Not surprisingly,
CK2 is essential for the infectious cycle of several viruses (Meggio and
Pinna, 2003). For instance, CK2-mediated phosphorylation of blue-
tongue virus NS2 protein is required for viral inclusion bodies forma-
tion in the host cell cytoplasm, and viral morphogenesis (Modrof et
al., 2005). CK2 also phosphorylates hepatitis C virus NS2 and NS5A pro-
teins, which inﬂuence the production of infectious virus particles
(Franck et al., 2005; Yi et al., 2009). CK2 regulates inﬂuenza virus bud-
ding at the plasma membrane (Hui and Nayak, 2002). The data pre-
sented here indicate that CK2 is required for efﬁcient cell-to-cell
spread and actin tail formation of VACV. Our results indicate that CK2
is not required for CEV formation, but stimulates Src recruitment to
CEVs, potentially through A36 phosphorylation.TBB 8 μM 
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Fig. 1. Inhibition of CK2 impairs actin-dependent spread of VACV. (A) Plaque phenotype of
mock-treated BS-C-1 cells or cells treated with 8 μM and 20 μM CK2 inhibitor TBB. No virus
overlay is presented as a percentage of the size relative to mock-treated cells. (B) Represen
stained with phalloidin (green channel) and VACV with an antibody recognizing A27 on
8 μM CK2 inhibitor TBB. (C) Quantitative analysis of the number of actin tails per cell in
TBB 20 μM). Data are presented as the mean±standard error of the mean. Compared to mResults and discussion
CK2 enhances VACV actin tail formation
To investigate a potential role for CK2 in vaccinia virus (VACV) in-
fection, we ﬁrst tested the effect of the CK2 inhibitor TBB on plaque
formation. BS-C-1 cells were infected with WR strain of VACV, over-
layed with liquid or semi-solid media containing different concentra-
tions of TBB, and stained at 2–3 days post-infection. Under semi-solid
overlay, we observed a 50% reduction in plaque size in cells treated
with 8 μM TBB, while increasing TBB to 20 μM reduced plaque size
to 20% compared to mock-treated cells (Fig. 1A). A reduction in pla-
que size potentially reﬂects a defect in cell-to-cell spread, which
may be related to a reduction in actin tail formation (Law et al.,
2002; Rodger and Smith, 2002; Roper et al., 1998; Ward et al., 2003;TBB 20 μM no virus
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, uninfected cells. Quantiﬁcation of plaque sizes for TBB-treated cells under semi-solid
tative images of HeLa cells infected with WR strain of VACV for 10 h. Actin tails were
the surface of IMV (red channel). Mock, mock-treated cells; TBB, cells treated with
mock-treated cells (mock), and cells treated with 8 μM or 20 μM TBB (TBB 8 μM and
ock, TBB 8 μM and 20 μM pb0.0001 (***).
145D.E. Alvarez, H. Agaisse / Virology 423 (2012) 143–151Wolffe et al., 1998). To test this possibility, we analyzed the ability of
VACV to form actin tails in cells treated with TBB. HeLa cells were
infected with WR strain of VACV and treated with either 8 or 20 μM
TBB, ﬁxed at 10 h, and stained with phalloidin to visualize actin tails
(Fig. 1B). We found a 3-fold reduction in the number of virus-tipped
actin tails per cell in cells treated with 8 μM TBB. When TBB concen-
tration was increased to 20 μM, the actin tail formation was reduced
by 10-fold (Fig. 1C). To conﬁrm the speciﬁcity of the observed pheno-
type, we analyzed the ability of VACV to form actin tails in cells de-
pleted of CK2 by RNA interference. HeLa cells were transfected with
two individual siRNA duplexes targeting CSNK2B expression (CK2siA
and CK2siB), a mix of these silencing reagents (CK2si mix), or a
non-targeting siRNA negative control. Three days post transfection
cells were infected with WR strain of VACV and actin tails counted
(Fig. 2A). Similar to the effect of CK2 inhibition with TBB, we observed
a 3-fold reduction in the number of actin tails in CK2-depleted cells
(Fig. 2B). We conﬁrmed the silencing efﬁcacy of the siRNA duplexes
at the protein and transcript levels (Figs. 2C and D). Altogether,
these data indicate that CK2 stimulates VACV actin tail formation.
Quantiﬁcation of CEV formation using a triple FLAG-tagged B5
membrane protein
A decrease in actin tail formation could reﬂect a defect in the re-
cruitment of the actin machinery to CEVs, or a defect in IEV releaseA
B
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Fig. 2. Actin tail formation is reduced in CK2-depleted cells. (A) Representative images of H
loidin (red channel) and VACV with an antibody recognizing A27 on the surface of IMV (g
CK2si, cells transfected with a siRNA duplex targeting CSNK2B. (B) Quantitative analysis o
siRNA duplexes targeting CSNK2B (CK2siA and CK2siB) or a pool of these siRNAs (CK2si mix
CK2siA p=0.0004 (***), CK2siB p=0.0020 (**), and CK2si mix p=0.0008 (***). (C and D) Ef
blot and normalized to actin levels (bottom panel) for mock-treated cells (mock) or cells dep
CSNK2B transcript levels.at the plasma membrane to form CEVs. To facilitate quantiﬁcation of
CEV formation, we constructed a recombinant VACV variant carrying
both an N-terminal fusion of A5L to mCherry and a triple-FLAG tagged
version B5R (vA5L-mCherry/3xF-B5R). A5 is present on the surface of
the core of IMV and it was reported to tolerate fusions at its N-
terminus without affecting virus morphogenesis or plaque size
(Carter et al., 2003). Thus, the A5-mCherry fusion protein should re-
veal all forms of VACV. On the other hand, B5 is a constituent of the
CEV and EEV membrane, and staining of B5 in non-permeabilized
cells should only reveal the CEV when released at the cell surface.
The N-terminus of B5 consists of four short consensus repeats
(SCRs) domains that are exposed on the surface of CEV and EEV par-
ticles (Engelstad et al., 1992). The SCR4 domain has been implicated
in inducing actin tail formation (Mathew et al., 1998; Newsome et
al., 2004). In addition B5R is required for formation of IEV and virus
spread (Engelstad and Smith, 1993; Wolffe et al., 1993). In order to
tag B5R without compromising its function, we introduced a triple-
FLAG epitope upstream from the SCR1 domain (Fig. 3A). Cells were
infected with either recombinant vA5L-mCherry/3xF-B5R or WR vi-
ruses and expression of 3xF-B5 was assessed by Western blot exper-
iments with a monoclonal antibody recognizing the FLAG epitope. As
expected, a speciﬁc species of 43 kDa was detected in the lysates from
cells infected with the recombinant virus, but was not detected in
cells infected with the WR virus or in non-infected cells (Fig. 3B).
We evaluated the ability of the vA5L-mCherry/3xF-B5R to spread bymock
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Fig. 3. Construction and characterization of recombinant VACV encoding A5L-mCherry and 3xF-B5R protein fusions. (A) Schematic representation of 3xF-B5 protein. 3xFLAG
(underlined) and ﬂanking B5 amino acid sequences are shown. SCR, short consensus repeat; TM, trans-membrane. (B) Detection of 3xF-B5 by western blot. Lysates from cells
infected with recombinant vA5L-mCherry/3xF-B5R or WR strain of VACV, and non-infected cells were resolved by SDS-PAGE and 3xF-B5R protein detected with a monoclonal an-
tibody against FLAG. Apparent molecular weights in the protein ladder are indicated on the left. (C) Plaque phenotype of WR strain and recombinant vA5L-mCherry/3xF-B5R VACV.
Plaque assays were performed in BS-C-1 cells with liquid (top panels) or semisolid (lower panels) overlay. Quantiﬁcation of plaque size for vA5L-mCherry/3xF-B5R is presented as a
percentage relative to WR parental strain. (D and E) Imaging of HeLa cells infected with vA5L-mCherry/3xF-B5R recombinant VACV. A5L-mCherry (red channel) reveals all the
forms of the virus. (D) Representative images of cells permeabilized with 0.1% Triton X-100 and stained for FLAG (green channel). (E) Representative images of non-
permeabilized cells. Arrows indicate co-localization of A5L-mCherry signal and FLAG staining corresponding to CEVs. Analysis of XZ reconstructions (top panels) show that CEVs
localize at the surface of the cell. Lines in the extended focus images (bottom panels) indicate Y coordinates.
146 D.E. Alvarez, H. Agaisse / Virology 423 (2012) 143–151comparing the plaque phenotype of recombinant and WR viruses
under liquid or semi-solid overlay in BS-C-1 cells. Under semi-solid
overlay, the recombinant virus and the parental WR virus strain
showed plaques that were comparable in size (Fig. 3C). With liquid
overlay WR virus forms a primary plaque and can also spread as
EEV to form comet satellite plaques. Recombinant vA5L-mCherry/
3xF-B5R formed plaques that were similar in size to WR, but was
not able to form comet satellite plaques (Fig. 3C). The impairment
in comet plaque formation would reﬂect an impairment in the pro-
duction of EEVs and was probably a consequence of the fusion of
mCherry to A5L, as previously reported for a VACV variant carryinga similar fusion of EGFP to the N-terminus of A5L (Carter et al.,
2003). To further characterize the recombinant virus, we investigated
the distribution of A5-mCherry and 3xF-B5 in HeLa cells at 10 h post
infection. A5-mCherry appeared as punctate structures that presum-
ably corresponded to IMVs (Fig. 3D, left and middle panels). In per-
meabilized cells, FLAG staining revealed the typical IEV envelope
pattern, with strong juxtanuclear localization, as well as discrete
puncta that may represent IEVs or CEVs (Fig. 3D, right panel). As
expected, in absence of permeabilization, FLAG staining did not reveal
the juxtanuclear viruses and only revealed extracellular viruses that
co-localized with mCherry signal at the plasma membrane (Fig. 3E).
147D.E. Alvarez, H. Agaisse / Virology 423 (2012) 143–151Thus, our recombinant vA5L-mCherry/3xF-B5R strain allows for spe-
ciﬁc detection of CEVs.
CK2 is not required for CEV formation
We next used the recombinant vA5L-mCherry/3xF-B5R strain to
determine whether CK2 is required for CEV formation. To this end,merge A5-mCherry
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Fig. 4. CK2 is not required for CEV formation. (A) Representative images of HeLa cells infect
meabilization (green channel). Colocalization of A5-mCherry signal (red channel) and FLAG
(blue channel). (B) Quantiﬁcation of the number of CEVs per cell. CEVs were counted in mo
mix), and cells treated with 8 μM CK2 inhibitor TBB or 33 μM nocodazole (noc). (C) Quantiﬁ
indicated. Data are presented as the mean±standard error of the mean.we quantiﬁed extracellular viruses in mock-treated, CK2-depleted
cells, and cells treated with 8 μM CK2 inhibitor TBB. This concentra-
tion of the drug was shown to result in a reduction of CK2 activity
with no induction of apoptosis (Duncan et al., 2008). Cells were
infected with vA5L-mCherry/3xF-B5R for 10 h and stained for FLAG
without permeabilization. Images were acquired from 30 cells for
each condition and the mean number of CEV per cell quantiﬁedαFLAG
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cation of the number of infectious particles released from WR-infected cells treated as
148 D.E. Alvarez, H. Agaisse / Virology 423 (2012) 143–151using computer-assisted image analysis to score for colocalization of
FLAG andmCherry signals (Fig. 4A). In this experiment, depolimeriza-
tion of microtubules with nocodazole was included as a control. As
expected, a 2 h treatment with nocodazole at 8 h post-infection im-
paired CEV formation resulting in a 10-fold decrease in the number
of CEV per cell as compared to mock-treated cells (Fig. 4B). In con-
trast, targeting CK2 with either siRNA or TBB treatment did not affect
CEV formation (Fig. 4B). These results suggest that CK2 is not in-
volved in virus assembly or microtubule transport of IEV to the plas-
ma membrane. Finally, we explored whether CK2 may play an
additional role in EEV release. To this end, cells were infected with
WR virus and at 24 h post infection the release of virus particles to
the media was quantiﬁed in a re-infection plaque assay. Consistent
with the decrease in CEV formation, the release of infectious virus
particles was reduced by 20-fold in nocodazole treated cells
(Fig. 4C). Conversely, virus release was comparable to control in
CK2-depleted cells. We observed a 2-fold reduction in virus release
in TBB-treated cells, which may reﬂect a CK2-independent side effect
of the drug. Taken together our results indicate that CK2 activity stim-
ulates VACV actin tail formation.
CK2 stimulates P-Src recruitment to CEV
In order to gain insight into the mechanism leading to the defect
in actin tail formation, we compared the localization of components
of the host cell actin polymerization machinery in mock- and CK2-
depleted cells. First, we quantiﬁed the recruitment of Arp2/3 to
CEVs and incorporation to associated actin tails in cells infected
with vA5L-mCherry/3xF-B5R. In agreement with actin tail counts
conducted in control cells (Fig. 2), we observed that 50% of CEVs
were associated with Arp3-decorated tails. As expected from our re-
sults showing a 3-fold decrease in CEVs displaying associated actin
tails in CK2-depleted cells (Fig. 2), CK2 depletion resulted in a 2.5-
fold decrease in CEVs displaying Arp3-decorated tails (Fig. 5B). We
noticed that, in control cells as well as in CK2-depleted cells, CEVs
that did not display Arp3-decorated tails did not display any co-
localization with Arp3. These results indicate that the decrease in
actin tail formation observed in CK2-depleted cells reﬂects a defect
in Arp2/3 recruitment to CEVs. We next quantiﬁed the localization
of N-WASP to CEVs and observed that recruitment of endogenous
N-WASP and Arp2/3 were reduced to a similar extent in CK2-
depleted cells (data not shown). Finally, we addressed whether the
actin tail formation defect was due to a defect in phospho-Src recruit-
ment. To this end, infected cells were immunostained with a mono-
clonal antibody recognizing the phosphorylated form of human Src
(Tyr418) (Fig. 6A, P-Src). Quantitative analysis of phospho-Src locali-
zation to CEVs revealed that CK2 depletion results in a 2-fold decreaseARP3 positive
ARP3 negative
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Fig. 5. CK2 enhances the recruitment of Arp2/3 to CEVs. (A) Representative images of HeL
without permeabilization (blue channel) was followed by permeabilization and staining o
of A5-mCherry signal (red channel) and FLAG staining, and scored as positive or negative
presented as the mean±standard error of the mean. p=0.0019 (**).in P-Src recruitment (Fig. 6B, P-Src). Altogether, our data suggest that
CK2 regulates VACV actin tail formation at an early stage, modulating
the recruitment of phospho-Src to CEVs. This observation may point
to a role for CK2 in the regulation of viral proteins involved in actin
tail formation such as A36, A33, or B5. In agreement with this as-
sumption, it was suggested that the bulk of the A36, which is associ-
ated with the endoplasmic reticulum, the Golgi network, or IEV, is
phosphorylated on serine residues (Wolffe et al., 2001). In addition,
we noticed that A36 displays several putative CK2 phosphorylation
motifs (SXXE/D; T58, S60, S62, and S69). It is therefore possible that
CK2 modulates Src recruitment to CEVs through A36 phosphoryla-
tion. We however do not exclude other potential mechanisms. In par-
ticular, it was shown that CK2 directly controls the activity of Src (and
several other kinases) through phosphorylation of the kinase-
associated molecular chaperone Cdc37 (Miyata and Nishida, 2004).
Further experiments will thus be required to determine the exact
role of CK2 in Src recruitment to CEVs.
Conclusion
To the best of our knowledge, this work is the ﬁrst report of a role
for CK2 in the dissemination of the viral pathogen, VACV. Recent data
from our group have demonstrated that CK2 is also required for the
dissemination of a bacterial pathogen, L. monocytogenes (Chong et
al., 2009). Thus, the cellular serine/threonine kinase CK2 emerges as
a common requirement among pathogens that rely on actin-based
dissemination for accomplishing their infectious cycle.
Materials and methods
Cells and viruses
HeLa (ATCC # CCL-2), HeLa S3 (ATCC # CCL-2.2), and BS-C-1
(ATCC # CCL-26) cells were grown in DMEM (Invitrogen) supplemen-
ted with 10% FBS (GIBCO) at 37 °C in a 5% CO2 incubator. VACV WR
and vB5R-GFP (Ward and Moss, 2001b) strains were kindly provided
by Bernard Moss. Viral strains were grown and propagated in HeLa
cells and plaque assays performed in BS-C-1 cells according to stan-
dard procedures (Earl et al., 1998a). Virus stocks were prepared
from HeLa S3 cells and partially puriﬁed by centrifugation through a
36% sucrose cushion (Earl et al., 1998b).
Plasmid construction
The gpt expression cassette was excised from pTK61-gpt vector
(Falkner and Moss, 1990) by EcoRI digestion and cloned into
EcoRI-digested pCR2.1-TOPO (Invitrogen) to generate pCR-gpt.α
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Fig. 6. Recruitment of P-Src to CEVs is impaired in CK2 depleted cells. (A) Representative images of HeLa cells infected with vA5L-mCherry/3xF-B5R recombinant VACV (top). FLAG
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149D.E. Alvarez, H. Agaisse / Virology 423 (2012) 143–151mCherry was fused to the N-terminus of A5L by PCR splicing by
overlap extension using VACV strain WR genomic DNA as a tem-
plate using the strategy described by Carter et al. (2003). Primers
(7) 5′-CGTACTCCGAGCTCGTGTAGATGCTACTTCGTCGATGG-3′ and
(8) 5′-GGCATGGACGAGCTGTACAAGGACTTCTTTAACAAGTTCTCACA-
GGGG-3′ were used to amplify a fragment containing the A5L
ORF and 342 bp downstream of the ORF. Primers (9) 5′-ATCCTCC-
TCGCCCTTGCTCACCATTTAAGGCTTTAAAATTGAATTGCG-3′ and (10)
5′-CTCCGTTCCTAGGGATGACTATAGGACAAGAACCCTCCTC-3′ were
used to amplify the 428 bp fragment upstream of A5L ORF. The
mCherry ORF was ampliﬁed using primers (11) 5′-CTTGTA-
CAGCTCGTCC-3′ and (12) 5′-GTGAGCAAGGGCGAG-3′ and plasmid
pRSET-B mCherry (Shaner et al., 2004) as a template. Primers
(8) and (9) contained mCherry sequences enabling the individual
fragments to be assembled into a single 2392 bp gene. This was
digested with SacI and AvrII and cloned into SacI and XbaI-
digested pCR-gpt to generate pA5L-EGFP-N.
To insert the triple-FLAG (3xF) epitope in B5R, primers (13) 5′-
GTATGAGCTCCCTTCTTTCGTGAAATGC-3′ and (14) 5′-CATGATCTTTA-
TAATCACCGTCATGGTCTTTGTAGTCCATTGTTGAATAAACAAC-3′ were
used to amplify 378 bp upstream of the B5R ORF and the ﬁrst 60 bp
of the ORF. Primers (15) 5′-TGATTATAAAGATCATGACATCGATTA-
CAAGGATGACGATTGTACTGTACCCACT-3′ and (16) 5′-GCTCTAGAGC-
TTACAGAAACATCGCGTT-3′ were used to amplify nucleotides 61 to
951 of B5R ORF and 340 bp downstream of the ORF. Primers (14)
and (15) contained 3xF sequences that allowed generating the PCR
fusion fragment. This was digested with SacI and XbaI and cloned
into SacI and XbaI-digested pCR-gpt to generate p3xF-B5R.
Construction of recombinant viruses
Recombinant viruses were obtained by transient dominant selec-
tion using gpt (Falkner and Moss, 1990). First, BS-C-1 cells were
infected with vB5R-GFP at 0.05 p.f.u. per cell, and transfected with
pA5L-mCherry-N using FuGene (Roche). Recombinant viruses
expressing gpt were subjected to two rounds of selection with myco-
phenolic acid (MPA) in BS-C-1 cells, followed by three rounds of pla-
que puriﬁcation of viruses that formed both green and red ﬂuorescent
foci. The resulting recombinant vA5L-mCherry/B5R-GFP was ampli-
ﬁed and analyzed by PCR. Primers (7) and (10) generated a DNA frag-
ment of 2.3 kb, conﬁrming that A5L-mCherry-N was inserted in the
A5L locus. No DNA ampliﬁcation was produced with primers (9)
and M13 forward (−20) 5′-GTAAAACGACGGCCAG-3′, conﬁrming
the loss of the gpt cassette. Finally, to replace B5R-GFP with 3xF-
B5R, cells were infected with vA5L-mCherry/B5R-GFP and transfectedwith p3xF-B5R. After selection withMPA, plaques were selected for the
loss of green ﬂuorescence. The resulting recombinant vA5L-mCherry/
3xF-B5R was analyzed by PCR. Primers (13) and (16) ampliﬁed a
1.7 kb DNA product that generated 1.3 and 0.4 kb fragments upon di-
gestion with ClaI, conﬁrming that B5R-GFP was replaced by 3xF-B5R
in the B5R locus. No DNA ampliﬁcation was produced with primers
(15) and M13 forward (−20), conﬁrming the loss of the gpt cassette.
CSNK2B silencing and validation procedure
Cells were transfected by reverse transfection with Dharmafect1
(Thermo Scientiﬁc) and individual CSNK2B siRNAs (A and B, 50 nM
ﬁnal) or a pool of the two silencing reagents (25 nM each, 50 nM
total) and were incubated for 72 h on coverslips in a 24-well plate
format. The sequences targeted by the individual siRNA duplexes
were as follows: A, CAACCAGAGUGACCUGAUU; B, GACAAGCUCUA-
GACAUGAU. Control cells were transfected with non-targeting Silencer
Negative Control #1 siRNA (Ambion).
For real-time PCR analysis, total RNA and ﬁrst-strand cDNA synthesis
was performed using the TaqMan Gene Expression Cells-to-Ct Kit (Ap-
plied Biosystems), as recommended by themanufacturer, with the addi-
tion of DNaseI for the removal of unwanted genomic DNA. mRNA levels
were determined by quantitative real-time PCR using the LightCycler
480 Master Kit and LightCycler 480 instrument (Roche Biochemicals,
Indianapolis, IN). The probes and primers were designed according to
Roche recommendation: http://www.roche-applied-science.com/sis/
rtpcr/upl/index.jsp?id=uplct_030000.CSNK2B transcript levelswere de-
termined using probe #28 and primers 5′-CTACCCCACCCCAGTCCT-3′
and 5′-TCCAGGACACCTCCTCTGA-3. GAPDH transcript levels were deter-
mined for normalization using probe #60 and primers 5′-AGCCA-
CATCGCTCAGACAC-3′ and 5′-GCCCAATACGACCAAATCC-3′.
For western blot analysis, cells were transfected with the corre-
sponding silencing reagents in a 24-well plate format, and lysed di-
rectly in Laemmli sample buffer. The anti-CSNK2B antibody (1:200)
was obtained from Santa Cruz (sc-20710). The anti-actin antibody
(1:10,000) was obtained from Sigma (A2066). The anti-rabbit HRP-
conjugated secondary antibody (1:10,000) was obtained from Jack-
son ImmunoResearch (111-035-14).
Immunoﬂuorescence procedures
HeLa cells were seeded on glass coverslips, grown to 30–50% con-
ﬂuency and infected with VACV at 10 p.f.u per cell. To synchronize the
infection, cells were incubated with the virus inoculum for 1 h at
room temperature, then washed three times with PBS, and after
150 D.E. Alvarez, H. Agaisse / Virology 423 (2012) 143–151adding fresh media, moved to 37 °C incubator. Where indicated, 8 μM
or 20 μM TBB (4,5,6,7-tetrabromo-1H-benzotriazole Casein kinase II
inhibitor I, Calbiochem) was added at 2 h post infection, or 33 μM
nocodazole at 8 h post infection. At 10 h post infection cells were
washed with cytoskeleton buffer (CB) (10 mM MES, 150 mM NaCl,
5 mM EGTA, 5 mM MgCl2, and 5 mM glucose, pH 6.1), ﬁxed in 3%
paraformaldehyde in CB for 10 min, and washed twice with CB. Sam-
ples were permeabilized and stained in 0.1% Triton X-100/2% BSA in
TBS (20 mM Tris, 154 mM NaCl, 2 mM EGTA, 2 mM MgCl2, pH 7.5)
containing the appropriate primary antibody for 2 h at room temper-
ature, and were washed three times in TBS before addition of second-
ary antibody for 1 h at room temperature. Coverslips were then
mounted onto glass slides using FluoroGuard Antifade Reagent (Bio-
Rad). Rabbit polyclonal antibody to VACV (1:1000) was obtained
from Abcam (ab35219), and mouse M2 monoclonal antibody anti
FLAG (1:1000) was obtained from Sigma (F3165). Alexa-ﬂuor sec-
ondary antibodies (1:1000), Alexa-ﬂuor conjugated phalloidin
(1:500), and Hoechst (1:500) were obtained from Invitrogen.
To detect CEVs at the cell surface, cells were blocked in 10% BSA/
TBS after ﬁxation, stained in 2% BSA/TBS containing the anti FLAG pri-
mary antibody for 30 min, and were washed ﬁve times in 2% BSA in
TBS before addition of secondary antibody. To quantify localization
of Arp3 to CEVs, cells were ﬁrst stained for surface FLAG, then blocked
and permeabilized in 10% BSA/0.1% Triton X-100 in TBS, and stained
with rabbit polyclonal anti-Arp3 antibody (1:200) obtained from Up-
state (07-272). Similarly, to score for P-Src recruitment to CEVs, sam-
ples were ﬁrst stained with a rabbit anti FLAG polyclonal antibody
(1:250) obtained from Sigma (F7425), and following permeabiliza-
tion, stained with a mouse monoclonal antibody anti-phospho-Src
(Tyr416) (1:200) obtained from Millipore (05-677). Alexa-ﬂuor 488
and Cascade Blue secondary antibodies (1:500) were obtained from
Invitrogen.
Immunoblotting
Protein samples were separated by SDS-PAGE and analyzed by im-
munoblot using HRP-conjugated secondary antibodies and Amer-
sham ECL western blotting detection reagents.
Computer-assisted image analysis
The number of CEVs per infected cell was determined by using
the analytical tools of the MetaMorph software. Appropriate
threshold of red channel identiﬁed objects corresponding to virus
particles expressing A5-mCherry. We next used the integrated
morphometry analysis (IMA) module to ﬁlter objects according
to size and create a mask displaying only single virus particles.
The same analysis was carried out for the green channel to identi-
fy objects corresponding to FLAG-B5-expressing CEVs. Finally using
the masks generated from the red and green channels as source
images we employed logical AND in the arithmetic function to de-
ﬁne and count CEVs as objects corresponding to colocalization of
A5-mCherry and FLAG-B5 signals.
In order to measure plaque sizes, ﬁrst we acquired grayscale im-
ages of crystal violet stained plates with a gel documentation system
using white-light illumination. Lysis plaques were identiﬁed by ap-
propriate threshold of light objects, and the area of individual objects
was quantiﬁed using the IMA module of the MetaMorph software.
Reinfection plaque assay
To measure the release of infectious virus particles, siRNA trans-
fection was performed in 24-well plates. Two days post-
transfection, conﬂuent monolayers of HeLa cells were infected with
WR virus at an moi of 10. At 2 h post infection, cells were washed
three times with PBS and serum-free media was added. Whereindicated, 8 μMTBB was added at 2 h post infection, or 33 μMnocoda-
zole at 8 h post infection. At 20 h post infection, cells were centri-
fuged and supernatant was removed. To assess virus release, the
supernatant was diluted 100-fold and used to infect fresh cells in 96
well-plates. 24 h later cells were ﬁxed and incubated with rabbit
polyclonal antibody to VACV followed by Alexa-Fluor secondary anti-
body immunostaining. Plaques were counted to measure the number
of infectious virus particles released into the supernatant from the
primary infection in the various conditions.
Statistical analysis
Quantitative analyses were performed in three independent ex-
periments and at least 30 cells from 20 independent images were
counted for each condition. Data are presented as mean±standard
error of the mean (SEM) and were analyzed by Student's t test
using Prism 5 (GraphPad Software, Inc.).
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